CDMT was the first original product of Jenapharm, an East German pharmaceutical company. It was patented in 1961. The idea of combining the structures of 4-chlorotestosterone (clostebol) and metandienone originated with chemist Albert Stachowiak. At the time, this represented a unique dissociation of anabolic from androgenic effects after oral administration. The product was introduced for clinical use in 1965 and remained in use until 1994, when production was discontinued.